CMS estimates that U.S. national healthcare expenditures exceeded $2.7 trillion
in 2011, representing 17.9% of total GDP. Increasingly, experts are focusing on the impact of medical
costs associated with chronic disorders, which the CDC estimate to be
responsible for as much as 75% of U.S. national healthcare expenditures. The
burden of chronic diseases, and their costs, will continue to rise as the U.S.
population simultaneously grows in size, becomes heavier, and ages.
As a case study, we look in depth at the multi-morbid HONDA
population in the United States. These patients concurrently have hypertension,
obesity, diabetes, and asthma and are notoriously noncompliant—each of these
diseases is a modifiable risk factor that both exacerbates and increases the
risk for severe complications and acute medical events that contribute to the
astronomical U.S. healthcare spend.
Questions Answered in This Report:
The United States leads the world in total
healthcare expenditure, with 2011 spend exceeding $2.7 trillion and forecast to
approach $4.8 trillion by 2021. What factors are driving the increase in
U.S. health expenditure? How does the United States compare with other
countries globally in terms of national healthcare expenditure and per capita
The HONDA patients are noncompliant and have
comorbid hypertension, obesity, diabetes, and asthma. This multi-morbid population
is prone to developing severe cardiovascular, diabetic, and renal complications
and is responsible for a significant proportion of total healthcare costs. What is the size of the prevalent HONDA population? What
U.S. counties represent HONDA hotspots, areas where severe, costly age-related
complications will cluster in the future?
Pharmaceutical expenditures for chronic diseases
are growing in the United States, and the drugs used to treat HONDA patients
are forecast to be among the highest selling and fastest growing from 2012-2019. What are the key strategies to capitalize on the
opportunities presented by HONDAs?
Markets covered: United States.
Epidemiology: U.S. county-specific prevalence of
hypertension, obesity, type 2 diabetes, asthma, and the multi-morbid
Primary research: Six interviewed experts:
- Medical director, U.S. health plan, <50,000
- Medical director, U.S. health plan, >7
- Medical director, U.S. health plan, >10
- Pharmacy director, U.S. health plan, >3
- Professor of Medicine, Section of Endocrinology,
Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine,
- Quality director, U.S. health plan, >250,000